Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$3,305.1B | 6.2 | $0.0 99.9% overvalued | 16.1% | $84.7M | ($109.5M) | 84.6% | (129.3%) | 48.9% | (104.9%) | 2.4% | |
$163.1B | 4.3 | $3.4 93.4% overvalued | (18.8%) | $11.8B | ($369.0M) | (15.9%) | (3.1%) | 18.2% | 4.9% | 95.7% | |
$160.6B | 4.2 | $0.0 99.4% overvalued | (34.3%) | $980.2M | ($5,489.0K) | (15.5%) | (0.6%) | (6.4%) | (11.0%) | 183.0% | |
$144.5B | 5.4 | $89.9 41.9% undervalued | (3.8%) | $195.6B | $15.9B | (10.7%) | 8.2% | 16.8% | 9.9% | 44.5% | |
$132.4B | 5.8 | $185.4 63.8% overvalued | 24.5% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$121.2B | 5.7 | $92.8 54.9% undervalued | 21.9% | $48.3B | $13.9B | 7.3% | 28.9% | 66.7% | 11.9% | 312.4% | |
$118.3B | 5.2 | $0.0 99.2% overvalued | (82.6%) | $114.4M | ($188.9M) | 11.1% | (165.0%) | (25.7%) | (45.6%) | 3.7% | |
$114.9B | 5.7 | $181.9 12.6% undervalued | (10.2%) | $66.5B | ($14.3B) | (14.5%) | (21.5%) | (3.0%) | (9.6%) | (1,376.2%) | |
$109.7B | 5.1 | $0.0 99.7% overvalued | 47.8% | $31.3M | ($59.8M) | 8.6% | (191.1%) | 1.3% | (35.3%) | 2.9% | |
$103.1B | 5.8 | $108.1 68.6% undervalued | 9.8% | $107.5B | $14.4B | (10.9%) | 13.4% | 28.8% | 30.3% | 23.9% | |
$99.8B | 7.2 | $106.2 82.1% undervalued | 42.3% | $20.4B | $8,611.0M | (4.9%) | 42.1% | 70.3% | 41.3% | (1,139.2%) | |
$92.3B | 5.3 | $78.1 89.3% undervalued | 44.9% | £26.2B | £10.0B | (52.1%) | 38.3% | 81.6% | (45.9%) | 0.0% | |
$89.1B | 7.3 | $108.7 70.1% overvalued | 13.1% | $3,953.6M | $1,101.9M | 29.4% | 27.9% | 74.9% | (7.3%) | 23.8% | |
$63.7B | 6.4 | $22.1 92.2% overvalued | 88.4% | $463.5M | ($22.1B) | (6.6%) | (4,777.0%) | 72.1% | (4.6%) | 0.9% | |
$60.8B | 6.4 | $200.5 85.5% undervalued | (23.3%) | £33.2B | £3,905.4M | 17.8% | 11.8% | 60.1% | 40.5% | 154.2% | |
$58.8B | 5.7 | $75.8 11.0% undervalued | 1.9% | $5,767.3M | $1,390.4M | 4.7% | 24.1% | 41.3% | (4.2%) | 30.3% | |
$55.8B | 6.6 | $190.0 13.4% overvalued | 11.4% | $4,795.0M | $1,392.6M | 23.2% | 29.0% | 81.7% | (16.5%) | 102.0% | |
$54.7B | 5.9 | $56.2 15.4% undervalued | 20.4% | $187.4B | ($5,980.0M) | 9.1% | (3.2%) | 12.5% | 9.2% | 1.5% | |
$50.2B | 6.3 | $111.0 28.1% overvalued | (1.2%) | $3,626.4M | $900.1M | 29.2% | 24.8% | 66.5% | (58.3%) | 87.1% | |
$49.8B | 6.5 | $534.5 50.8% undervalued | 19.7% | $55.1B | $3,161.0M | 0.9% | 5.7% | 55.0% | 15.5% | 476.6% |
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Stay informed on the latest stocks trading at 52-week lows, highlighting those facing downward pressure in the market.
Explore 20 stocks in the Warren Buffett favorites stocks portfolio 2025, managed by Berkshire Hathaway.